<DOC>
	<DOC>NCT00799903</DOC>
	<brief_summary>This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.</brief_summary>
	<brief_title>The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial</brief_title>
	<detailed_description>Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, and every 6 months until the end of the study. Average time in the study for an individual subject is expected to be about 3 years.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Men or women at least 18 years old. Women must be postmenopausal or using a highly effective method for avoidance of pregnancy. Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject. Chronic coronary heart disease At least one of the following: At least 60 years old Diabetes requiring treatment with medication Low HDL cholesterol ("good cholesterol") Currently smoke cigarettes or stopped smoking within the past 3 months Diagnosed mild or moderate reduction in kidney function Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease. Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure. Liver disease Severe reduction in kidney function OR removal of a kidney OR kidney transplant Severe heart failure Blood pressure higher than normal despite lifestyle changes and treatment with medications Any lifethreatening disease expected to result in death within the next 2 years (other than heart disease) Severe asthma that is poorly controlled with medication Pregnant (Note: A pregnancy test will be performed on all nonsterile women prior to study entry) Previous severe allergic response to food, drink, insect stings, etc. Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study. Certain medications that may interfere with the study medication (these will be identified by the study doctor) Participation in a study of an investigational medication within the past 30 days Current participation in a study of an investigational device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart disease</keyword>
	<keyword>Lp-PLA2 inhibitor</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>CV risk</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>